Related Experiment Video
Updated: Jun 23, 2026
08:24
A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model
Published on: November 25, 2022
Modulation of alpha-synuclein aggregation by dopamine: a review
Su Ling Leong1, Roberto Cappai, Kevin Jeffrey Barnham
1Department of Pathology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, VIC 3010, Australia.
Neurochemical Research
|May 16, 2009
Summary
Parkinson's disease involves dopamine neuron loss and alpha-synuclein aggregation. Dopamine oxidation may drive these processes, impacting protein metabolism and neuronal health.
Area of Science:
- Neurodegenerative diseases
- Molecular neuroscience
- Parkinson's disease pathogenesis
Background:
- Parkinson's disease (PD) is marked by dopaminergic neuron loss and alpha-synuclein (alpha-syn) aggregation into Lewy bodies.
- The interaction between dopamine (DA) and alpha-syn is implicated in neuronal death and protein misfolding in PD.
- The precise mechanisms linking DA, alpha-syn, and PD pathology remain incompletely understood.
Purpose of the Study:
- To review existing literature on the role of dopamine and its oxidative byproducts.
- To explore how dopamine oxidation influences alpha-synuclein aggregation pathways.
- To elucidate the potential contribution of dopamine oxidation to Parkinson's disease pathogenesis.
Main Methods:
- Literature review of studies investigating dopamine, alpha-synuclein, and Parkinson's disease.
- Analysis of research on dopamine oxidation and its effects on protein aggregation.
- Synthesis of findings related to oxidative stress, mitochondrial dysfunction, and protein metabolism in PD.
Main Results:
- Dopamine oxidation products are suggested to induce oxidative stress and mitochondrial dysfunction.
- These oxidative processes may impair protein metabolism, favoring alpha-synuclein aggregation.
- The interplay between dopamine oxidation and alpha-synuclein aggregation is a critical factor in neuronal damage.
Conclusions:
- Dopamine oxidation is a significant factor in Parkinson's disease pathogenesis.
- Oxidative intermediates of dopamine may directly modulate alpha-synuclein aggregation.
- Further research into this interaction could reveal novel therapeutic targets for Parkinson's disease.
Related Concept Videos
01:37Neural Regulation
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:24Parkinson Disease l: Introduction
Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...